Quidel Corp (QDEL) Tops Q2 EPS by 12c, Slight Beat on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Quidel Reports Second Quarter 2018 Financial Results
August 7, 2018 4:10 PM EDTSAN DIEGO--(BUSINESS WIRE)-- Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the second quarter ended June 30, 2018.
Second Quarter 2018 Highlights
Total revenue was $103.2 million as compared to $38.3 million in the second quarter of 2017. Cardiac Immunoassay revenue was $69.9 million. Influenza revenue was $5.5 million as compared to $10.1 million in the second quarter of 2017. Reduced debt by an additional $98.6 million through convertible note... More